Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Pancreas Cancer
100%
Gemcitabine
66%
Overall Survival
46%
Voiding Dysfunction
33%
Irreversible Electroporation
33%
Liver Metastasis
33%
Protein Expression
33%
Tumor
33%
Breast Cancer Resistance Protein
33%
Esophageal Adenocarcinoma
33%
Chemotherapy
33%
Multivariate Analysis
24%
Leukocyte
22%
Clinical Stage
22%
Recurrent Disease
22%
Randomized Clinical Trials
22%
Prognostic Factor
22%
Second Cancer
22%
Preoperative Chemotherapy
22%
Progression Free Survival
20%
Combination Chemotherapy
16%
Postoperative Complication
13%
Immunotherapy
11%
Pembrolizumab
11%
Cancer Control
11%
Lymphocyte
11%
Comorbidity
11%
Cell Count
11%
Recurrence Free Survival
11%
Lactate Dehydrogenase
11%
Radical Surgery
11%
Plummer-Vinson Syndrome
11%
Charlson Comorbidity Index
11%
Neoplasm
7%
Upregulation
7%
Monotherapy
6%
Tumor Microenvironment
5%
Tumor Progression
5%
Neutrophil
5%
T Cell
5%
Biopsy
5%
Immunocompetent Cell
5%
Plasmacytoid Dendritic Cell
5%
Programmed Death-Ligand 1
5%
Gene Expression
5%
down Regulation
5%
Effector Cell
5%
Biological Marker
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
66%
Gemcitabine
66%
Paclitaxel
66%
Chemotherapy
58%
Postoperative Complication
41%
Retrospective Study
33%
Incontinence
33%
Clinical Trial
33%
Effusion
33%
Esophageal Adenocarcinoma
33%
Overall Survival
33%
Pancreas Adenocarcinoma
23%
Second Cancer
16%
Randomized Clinical Trial
16%
Recurrent Disease
16%
Comorbidity
16%
Maximum Tolerated Dose
9%
Recurrence Free Survival
8%
Dysphagia
8%
Lactate Dehydrogenase
8%
Malignant Neoplasm
8%
Progression Free Survival
8%
Monotherapy
6%
Immunology and Microbiology
Electroporation
66%
Pembrolizumab
44%
Pancreas
33%
Immunity
33%
Progression Free Survival
33%
Protein Expression
33%
ABCG2
33%
Immunotherapy
27%
Overall Survival
26%
Interleukin-6
16%
Recommended Drug Dose
16%
Preclinical Study
13%
Plasmacytoid Dendritic Cell
13%
Effector Cell
13%
T Cell
13%
Immunocompetent Cell
13%
Cytokine
8%
Upregulation
7%
Myeloid-Derived Suppressor Cell
5%
Programmed Death-Ligand 1
5%
Gene Expression
5%
Neutrophil Granulocyte
5%
Downregulation
5%